Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Placebo-Controlled, Multicenter, Randomized Phase 2 Trial Evaluating the Efficacy and Safety of Felzartamab Compared to Placebo in Adult Participants With Graves' Disease

NCT07722546 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT07722546
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07722546 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Placebo-Controlled, Multicenter, Randomized Phase 2 Trial Evaluating the Efficacy and Safety of Felzartamab Compared to Placebo in Adult Participants With Graves' Disease
Lead sponsor
Biogen
Phase
Phase 2
Overall status
Recruiting
Start date
July 30, 2026
Completion date
March 31, 2028
Enrollment
60 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

graves' disease